CLSD
- Clearside Biomedical, Inc.
()
Overview
Company Summary
Clearside Biomedical, Inc. (CLSD) is a pharmaceutical company focused on developing and commercializing innovative treatments for sight-threatening diseases of the eye. They specialize in utilizing a proprietary technology called Suprachoroidal Space (SCS) microinjection, which allows targeted delivery of drugs to the affected area of the eye.
Clearside Biomedical leverages its expertise in drug formulation, device development, and clinical research to create therapies that can improve the treatment of various eye disorders. Their primary focus is on developing treatments for diseases which affect the back of the eye, such as macular edema associated with retinal vein occlusion (RVO), uveitis, and diabetic macular edema (DME).
The company's investigational SCS microinjection technique enables the targeted administration of drugs to the suprachoroidal space, a region of the eye that houses key structures involved in vision. By delivering drugs directly to this area, Clearside Biomedical aims to enhance drug effectiveness, reduce side effects, and provide improved patient outcomes compared to traditional delivery methods.
Clearside Biomedical is actively engaged in research and development, conducting clinical trials to evaluate the safety and efficacy of their treatments. Their goal is to create therapies that can provide better visual outcomes and quality of life for patients suffering from sight-threatening eye diseases.
In summary, Clearside Biomedical develops innovative therapies for eye diseases using their proprietary SCS microinjection technology, with a focus on improving treatment outcomes and reducing side effects for patients with retinal vein occlusion, uveitis, and diabetic macular edema.